EICHOR
● Active Not Recruiting
Prevention Atrial Fibrillation by BOTulinum Toxin Injections (BOTAF)
Condition: Cardiac Surgery · Sponsor: Assistance Publique - Hôpitaux de Paris
About this study
Over the past few years, research has focused on the prevention of atrial fibrillation (AF) after cardiac surgery, but highly effective interventions are still missing. Postoperative AF remains the most common complication after cardiac surgery, with an incidence of 10 to 50%. This complication is usually a transient condition that resolves spontaneously but it has major adverse consequences for patients and the health care system, including increased rates of death, complications (strokes), and hospitalisations with inflated costs. Recently, animal studies have demonstrated that neurotoxins such as botulinum toxin (BTX) injected into fat pads could suppress AF inducibility by parasympathetic activation. Botulinum toxin injection in fat pads has been studied in the dog's heart and could be associated with the reduction of atrial fibrillation in postoperative cardiac surgery. One pilot study has demonstrated the feasibility and safety of this technique in the human heart. The investigators hypothesize that botulinum toxin injection may substantially reduce postoperative AF during the first postoperative month after cardiac surgery without any serious adverse events. By the suppression of ganglionic plexi (GP) activity in the epicardial fat pads, mild term antiarrhythmic effects can be achieved with fewer antiarrhythmic drugs and anticoagulant treatment.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (7)
| Corentin Celton | Issy-les-Moulineaux, France, France | — |
| Hôpital Marie Lannelongue | Le Plessis-Robinson, France, France | — |
| CHU Limoges | Limoges, France, France | — |
| Hôpital Saint-Joseph | Marseille, Provence-Alpes-Côte d'Azur Region, France | — |
| Clinique Ambroise Paré | Neuilly-sur-Seine, Île-de-France Region, France | — |
| Institut Mutualiste Montsouris | Paris, Île-de-France Region, France | — |
| Hôpital Européen Georges Pompidou | Paris, Île-de-France Region, France | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04075981